Woong Sub Byun
Overview
Explore the profile of Woong Sub Byun including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
47
Citations
288
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Geng Q, Jiang Z, Byun W, Donovan K, Zhuang Z, Jiang F, et al.
J Med Chem
. 2025 Jan;
68(3):3180-3196.
PMID: 39873536
Molecular glue degraders (MGDs) are small molecules that facilitate proximity between a target protein and an E3 ubiquitin ligase, thereby inducing target protein degradation. Glutarimide-containing compounds are MGDs that bind...
2.
Han J, Yang S, Byun W, Jang S, Bae E, Park H, et al.
Eur J Pharm Sci
. 2024 Dec;
205():106991.
PMID: 39689820
Castrate-resistant prostate cancer (CRPC) is one of the most difficult cancers in men and is characterized by a poor prognosis and a high risk of metastasis. The overexpression of the...
3.
Zhu X, Byun W, Pienkowska D, Nguyen K, Gerhartz J, Geng Q, et al.
bioRxiv
. 2024 Nov;
PMID: 39554093
is the most commonly mutated gene in cancer, but it remains recalcitrant to clinically meaningful therapeutic reactivation. We present here the discovery and characterization of a small molecule chemical inducer...
4.
Razumkov H, Jiang Z, Baek K, You I, Geng Q, Donovan K, et al.
J Am Chem Soc
. 2024 Nov;
146(46):31433-31443.
PMID: 39499896
Small molecules promoting protein-protein interactions produce a range of therapeutic outcomes. Molecular glue degraders exemplify this concept due to their compact drug-like structures and ability to engage targets without reliance...
5.
Zhuang Z, Byun W, Kozicka Z, Dwyer B, Donovan K, Jiang Z, et al.
bioRxiv
. 2024 Oct;
PMID: 39386645
Targeted covalent inhibition (TCI) and targeted protein degradation (TPD) have proven effective in pharmacologically addressing formerly 'undruggable' targets. Integration of both methodologies has resulted in the development of electrophilic degraders...
6.
Hassan M, Li Y, Ma M, Teng M, Byun W, Puvar K, et al.
Eur J Med Chem
. 2024 Sep;
279:116904.
PMID: 39341093
Chemically induced proximity modalities such as targeted protein degradation (TPD) hold promise for expanding the number of proteins that can be manipulated pharmacologically. However, current TPD strategies are often limited...
7.
Bae E, Hong J, Lim Y, Byun W, Chun S, Hong S, et al.
J Med Chem
. 2024 Aug;
67(17):14885-14911.
PMID: 39151060
As an obstinate cancer pancreatic cancer (PC) poses a major challenge due to limited treatment options which include resection surgery, radiation therapy, and gemcitabine-based chemotherapy. In cancer cells, protein kinase...
8.
Li Y, Ma M, Hassan M, Hunkeler M, Teng M, Puvar K, et al.
Nat Chem Biol
. 2024 Jul;
20(12):1640-1649.
PMID: 39075252
Molecular glues are proximity-inducing small molecules that have emerged as an attractive therapeutic approach. However, developing molecular glues remains challenging, requiring innovative mechanistic strategies to stabilize neoprotein interfaces and expedite...
9.
Ji W, Du G, Jiang J, Lu W, Mills C, Yuan L, et al.
Eur J Med Chem
. 2024 Jul;
276:116613.
PMID: 39004018
Cyclin-dependent kinase 7, along with cyclin H and MAT1, forms the CDK-activating complex (CAK), which directs cell cycle progression via T-loop phosphorylation of cell cycle CDKs. Pharmacological inhibition of CDK7...
10.
Razumkov H, Jiang Z, Baek K, You I, Geng Q, Donovan K, et al.
bioRxiv
. 2024 May;
PMID: 38746375
Small molecules promoting protein-protein interactions produce a range of therapeutic outcomes. Molecular glue degraders exemplify this concept due to their compact drug-like structures and ability to engage targets without reliance...